Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Feb 20, 2001
SAN DIEGO, Feb. 20 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the completion of the acquisition of the outstanding capital stock of Bunsen Rush Laboratories, Inc. via merger with Arena's wholly-owned subsidiary, BRL Screening, Inc. BRL Screening is a Delaware corporation headquartered in San D...
Jan 31, 2001
SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the signing of an expansion amendment to its May 29, 2000 research agreement with Taisho Pharmaceutical Co., Ltd. ("Taisho") by which Taisho has received world-wide rights to Arena's 18F Program. In addition to potential future mile...
Jan 18, 2001
SAN DIEGO, Jan. 18 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended December 31, 2000. During the fourth quarter 2000, the Company reported revenues of $4.1 million versus no revenues for the fourth quarter of 1999. Revenues in the fourth quarter of 2000 were attributable to colla...
Jan 15, 2001
SAN DIEGO, Jan. 15 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli Lilly and Company (NYSE: LLY), Arena has received $1.5 million in milestone payments from Lilly in the fourth quarter of 2000. These milestone pa...
Jan 4, 2001
SAN DIEGO, Jan. 4 /PRNewswire/ Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host both a telephone and internet fourth quarter conference call on Thursday, January 18, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, ...
Dec 27, 2000
SAN DIEGO and DALLAS, Dec. 27 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") and Bunsen Rush Laboratories, Inc. ("Bunsen Rush"), a privately-held corporation, today jointly announced the signing of a Binding Letter of Intent & Memorandum of Agreement ("Agreement") for Arena to acquire all of the outstanding ca...
Nov 29, 2000
SAN DIEGO, Nov. 29 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of a Notice of Allowance ("Allowance") from the United States Patent and Trademark Office directed to a method of identifying inverse agonists to a CART-activated human serotonin receptor. An Allowance indicates that all of the r...
Oct 25, 2000
SAN DIEGO, Oct. 25 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - news) today reported results for the quarter ended September 30, 2000. During the third quarter 2000, the Company reported revenues of $2.3 million versus no reven...
Oct 23, 2000
SAN DIEGO, Oct. 23 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its May 29, 2000 research agreement with Taisho Pharmaceutical Co., Ltd., Arena has achieved several financial research and development milestones. These milestones are related to acceptance by Taisho of a CART-activat...
Oct 12, 2000
SAN DIEGO, Oct. 12 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host both a telephone and internet third quarter conference call on Wednesday, October 25, 2000 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Moon...
Sep 25, 2000
SAN DIEGO, Sept. 25 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli Lilly and Company, Arena has received its first research milestone payments from Eli Lilly. These milestone payments are related to acceptance b...
Sep 6, 2000
SAN DIEGO, Sept. 6 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended June 30, 2000. During the second quarter 2000, the Company reported revenues of $1.3 million versus no revenues for the second quarter of 1999. Revenues in the second quarter of 2000 were attributable to new coll...
Aug 22, 2000
SAN DIEGO, Aug. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of United States Patent Number 6,107,324 entitled "Non-Endogenous Constitutively Activated Human Serotonin Receptors and Small Molecule Modulators Thereof." This is the first patent issued to Arena since its inception in April of...
Aug 10, 2000
SAN DIEGO, Aug. 10 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriters led by ING Barings LLC, Prudential Securities Incorporated, and SG Cowen Securities Corporation, have exercised in full their over-allotment option in connection with Arena's initial public offering, and purchased an addi...
Aug 1, 2000
THE WOODLANDS, Texas, Aug. 1 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) today announced the formalization of a joint research collaboration with Arena Pharmaceuticals (Nasdaq: ...
= add release to Briefcase